Clinical Trial Update: Panobinostat With Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating panobinostat in combination with rituximab for relapsed/refractory diffuse large B-cell lymphoma was terminated, with results posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Farydak (panobinostat)
• Rituxan (rituximab)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Diffuse Large B Cell Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2017-03-31